Τόμος 24 (2006) – Τεύχος 3 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 24 (2006) – Issue 3 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Ματθαίος Διδάγγελος, Σοφία Λέββα και Λιάνα Φιδάνη

Εργαστήριο Γενικής Βιολογίας και Γενετικής, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

M. Didangelos, S. Levva and L. Fidani

Laboratory of General Biology and Genetics, School of Medicine, Aristotle University, Thes­saloniki GR-54124, Hellas

2. Juengst T.E.: What’s next for human gene therapy? BMJ 326: 1410-1411 (2003)

3. Longman J.: Pushing the Limits: Getting the Athletic Edge May Mean Altering Genes. The New York Times; Available at: http://www.nytimes.com/2001/05/11/sports/11GENE.html (2001)

4. WADA (The World Anti-Dopind Agency): Gene Doping. Play True, Issue 1: 2-6 (2005)

5. WADA: The prohibited list 2005, WADA publications, September 2004

6. WADA: The prohibited list 2006, WADA publications, September 2005

7. WADA: http://www.wada-ama.org

8. DiCecco J.: Gene Doping: Creating the Super-athlete. Biomed. Semin. I (25/02/02)

9. Haisma H.J. Prof. Dr., O. de Hon, P. Sollie and J. Vor­stenbosch: Gene Doping. Topical Publications by the Netherlands Centre for Doping affairs (NeCeDo), February 2004

10. Williams D.A., Nienhuis A.W., Hawley R.G., Smith F.O,: Gene therapy 2000. Hematology (Am. Soc. Hematol. Educ.): 376–393 (2000)

11. Andersen J.L., Schjerling P., and Saltin B.: Muscle, Genes and Athletic Performance. Scientific American 283(3): 48-55 (2000)

12. Barton Davis R.E., Shoturma I.D., Musaro A., Rosen­thal N., Sweeney H.L.: Viral mediated expression of insu­lin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc. Natl. Acad. Sci. USA 95: 15603-15607 (1998)

13. Huard J., Li Y., Peng H.R., Fu F.H.: Gene therapy and tissue engineering for sports medicine. J. Gene Med. 5: 93-108 (2003)

14. MartinekV.,FuF.H., HuardJ.: Gene therapy and tissue engineering in sports Medicine. Phys. Sports Med. 28 No.2: (2000)

15. Chikuni K., Nakajima I., Mika OE., Muroya S.: Perox­isome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha) expression and the formation of slow-twitch muscle fibers in porcine and bovine skeletal mus­cles. Animal Sci. J. 76: 375 (2005)

16. Lindpaintner K.: Pharmacogenetics and pharmacoge­nomics in drug discovery and development: an overview. Clin. Chem. Lab. Med. 41: 398-410 (2003).

17. Montgomery H., Clarkson P., et al.: Angiotension-con­verting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 353: 541-545 (1999)

18. Montgomery H., Marshall R., et al.: Human Gene for Physical Performance. Nature 393: 221-222 (1998)

19. Rankinen T., Perusse L., Rauramaa R., Rivera M.A., Wolfarth B., Bouchard C.: The human gene map for per­formance and health-related fitness phenotypes. Med. Sci. Sports Exerc 33: 855-867 (2001)

20. Rankinen T., Perusse L., Rauramaa R., Rivera M.A., Wolfarth B., Bouchard C.: The human gene map for per­formance and health-related fitness phenotypes: the 2001 update. Med. Sci. Sports Exerc. 34:1219-1233 (2002)

21. Rankinen T., Perusse L., Rauramaa R., Rivera M.A., Wolfarth B., Bouchard C.: The human gene map for per­formance and health-related fitness phenotypes: the 2002 update. Med. Sci. Sports Exerc. 35: 1248-1264 (2003)

22. Rankinen T., Perusse L., Rauramaa R., Rivera M.A., Wolfarth B., Bouchard C.: The human gene map for per­formance and health-related fitness phenotypes: the 2003 update. Med. Sci. Sports Exerc. 36: 1451-1469 (2004)

23. Verma I.M.: Doping, Gene Transfer and Sport (Edito­rial). Mol. Ther. 10: 405 (2004)

24. Russell G., Gore C.J., Ashenden M.J., Parisotto R., Hahn A.G.: Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur. J. Appl. Physiol. 86: 442-449 (2002)

25. Souillard A., Audran M., Bressolle F., Gareau R., Du­vallet A., Chanal J.L.: Pharmacokinetics and pharmacody­namics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br. J. Clin. Pharmacol. 42: 355-360 (1996)

26. Varlet-Marie E., Audran M., Lejeune M., Bonafoux B. et al.: Analysis of human reticulocyte genes reveals altered erythropoiesis: potential use to detect recombinant human erythropoietin doping. Haematologica 89: 991-997 (2004)

27. Audran M., Gareau R., Matecki S., Durand F., Chenard C., Sicart M.T., et al.: Effects of erythropoietin administra­tion in training athletes and possible indirect detection in doping control. Med. Sci. Sports Exerc. 31: 639-645 (1999)

28. Birkeland K., Stray-Gundersen J., Hemmersbach P., et al.: Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med. Sci. Sports Exerc. 32: 1238-1243 (2000)

29. Diamanti-Kandarakis E., Konstantinopoulos P.A., Pa­pailiou J., Kandarakis S.A., Andreopoulos A., Sykiotis G.P.: Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med. 35: 831-840 (2005)

30. Lasne F.: Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in im­munoblotting procedures. J. Immunol. Meth. 253: 125-131 (2001)

31. Magnani M., Corsi D., Bianchi M., Paiardini M., Gal­luzzi L., Gargiullo E., et al.: Identification of blood erythroid markers useful in revealing erythropoietin abuse in Ath­letes. Blood Cells Mol. Dis. 27: 559-571 (2001)

32. Davidson College Biology Department: http://www.bio.davidson.edu

33. Gao G., Lebherz C., Weiner D.J., Grant R., Calcedo R., Bagg A., Zhang Y., Wilson J.M.: Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103: 3300-3302 (2004)

34. Zhou S., Murphy JE., Escobedo JA., Dwark VJ.: Adeno-associated virus mediated delivery of erythropoiet­inleads to sustained elevation of hematocrit in nonhuman primates. Gene Ther. 5: 665-670 (1998)

35. McCrory P.: Super athletes or gene cheats? Br. J. Sports Med. 37: 192–193 (2003)

36. Lee S.H.: Gene Doping. Scientific American 291(1): 62-69 (2004)

37. Lee S., et al.: Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. J. Appl. Physiol. 96: 1097–1104 (2004)

38. Lee S.J., McPherron A.C.: Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. USA 98: 9306-9311 (2001)

39. Lin C.R., Yang L.C., Lee T.H., Lee C.T., Huang H.T., Sun W.Z., Cheng J.T.: Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther. 9: 1247-1253 (2002)

40. Smith O.: Biomedicine – Pain-killer genes. Science 284: 1634 (1999)

41. Losordo D.W., Vale P.R., Hendel R.C., Milliken C.E., Fortuin F.D., Cummings N., et al.: Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105: 2012-2018 (2002)

42. Losordo D.W., Vale P.R., Symes J.F., Dunnington C.H., Esakof D.D., Maysky M., et al.: Gene therapy for myocardial angiogenesis – Initial clinical results with direct myocardial injection of phvEGF(165) as sole therapy for myocardial ischemia. Circulation 98: 2800-2804 (1998)

43. Baumgartner I., Pieczek A., Manor O., Blair R., Kear­ney M., Walsh K., et al.: Constitutive expression of phVEGF(165) after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114-1123 (1998)

44. Rajagopalan S., Mohler E.R.,III, Lederman R.J., Men­delsohn F.O., Saucedo J.F., Goldman C.K., et al.: Re­gional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, dou­ble-blind, controlled study of adenoviral delivery of vascu­lar endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933-1938 (2003)

45. Wang Y.X., Zhang C.L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., et al.: Regulation of muscle fiber type and running endurance by PPARd. PLoS Biol­ogy 2(Issue 10) e294: 1532-1539 (2004)

46. Bidlingmaier M., Wu Z., Strasburger CJ.: Doping with growth hormone. J. Pediatr. Endocrinol. Metab. 14:1077-1083 (2001)

47. Griscelli F., Opolon P., Saulnier P., Mami-Chouaib F., Gautier E., Echchakir H., et al.: Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther. 10: 386-395 (2003)

48. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., et al.: A serious ad­verse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348: 255-256 (2003)

49. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., et al.: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metabol. 80: 148–158 (2003)

50. Tenenbaum L., Lehtonen E., Monahan P.E.: Evalua­tion of risks related to the use of adeno-associated virus-based vectors. Curr. Gene Ther. 3: 545-565 (2003)

51. Zarembo A.: Dangers of Gene Doping in Sports. Los Angeles Times (November 2004)

52. Arruda V.R., Fields P.A., Milner R., Wainwright L., De Miguel M.P., Donovan P.J., et al.: Lack of germline trans­mission of vector sequences following systemic admini­stration of recombinant AAV-2 vector in males. Mol. Ther. 4: 586-592 (2001)

53. Breidbach A., Catlin D.H., Green G.A., Tregub I., Truong H., Gorzek J.: Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin. Chem. 49: 901–907 (2003)

54. ACF News Source: http://www.acfnewsource.org/science/barcoded_blood.html

55. Ye X., Rivera V.M., Zoltick P., Cerasoli F.,Jr., Schnell M.A., Gao G., et al. : Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283: 88-91 (1999)

56. Lasne F., Martin L., de Ceaurriz J., Larcher T., Moullier P., Chenuaud P.: Genetic Doping with erythropoietin cDNA in primate muscle is detectable. Mol. Ther. 10: 409-10 (2004)

57. Friedmann T., Koss J.O.: Gene transfer and athletics – An impending problem. Mol. Ther. 3: 819-820 (2001)

58. IOC: http://www.olympic.org

59. NeCeDo: http://www.necedo.nl

60. Miah A.: Gene-Doping: Sport. Values & Bioethics (Glasa J., ed.): The Ethics of Human Genetics; Strasburg, Council of Europe, pp.171-180